A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer (NCT05318573)
A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Who can join: Review the eligibility criteria below.
Location: Cancer and Blood Speciality Clinic — Long Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- Cancer and Blood Speciality Clinic — Long Beach, California
- Sharp Memorial Hospital (Oncology Clinical Research) — San Diego, California
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- University of Kansas Cancer Center - Westwood — Westwood, Kansas
- University of Kentucky Medical Center — Lexington, Kentucky
- University of Louisville Brown Cancer Center — Louisville, Kentucky
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan
- Washington University School of Medicine, Center for Adv Medicine — St Louis, Missouri
- Nebraska Cancer Specialists - Legacy — Omaha, Nebraska
- Comprehensive Cancer Centers of Nevada - Southern Hills — Las Vegas, Nevada
- Atlantic Health System / Morristown Medical Center — Morristown, New Jersey
- NYU Langone Health — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- TriHealth Cancer Institute; Good Samaritan Hospital — Cincinnati, Ohio
- Providence Cancer Institute Franz Clinic — Portland, Oregon
- Hospital of the Univ of Pennsylvania Perlman Center — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- Avera Cancer Institute — Sioux Falls, South Dakota
- Sarah Cannon Research Institute — Nashville, Tennessee
- University of Texas Southwestern Medical Center — Dallas, Texas
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- University of Wisconsin Clinical Science Center — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Urothelial Carcinoma
- A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma — San Francisco, California
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction — Beverly Hills, California
- Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer — West Haven, Connecticut
Explore by condition: All Advanced Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.